Latest Breaking News On - Birgit stattin norinder - Page 1 : comparemela.com
Hansa Biopharma interim report Jan-Mar 2021
First commercial sales of Idefirix
® recorded in Q1; New preclinical collaboration with argenx; Encouraging three-year follow-up data in kidney transplantation
Hansa Biopharma AB
Publicerad: 22 april 2021, 08:00
Lund, Sweden April 22, 2021 Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and interim report for January – March, 2021
.
First commercial sales of Idefirix
® recorded in Q1 2021 following treatment of the first patients. Commercial launch activities in early launch countries continue to be carried out as planned. National level reimbursement application processes underway and decisions by authorities in the first markets expected from mid-year and onwards.
SwedenUnited-statesUnited-kingdomSwedishHilary-maloneHansa-biopharmaBirgit-stattin-norinderMagnus-korsgrenKlaus-sindahlDonato-spotaKatja-margellReata-pharmaceuticalsShare this article
Share this article
LUND, Sweden, April 9, 2021 /PRNewswire/ Hansa Biopharma AB (publ), Reg. No. 556734-5359, with registered office in Lund, gives notice to Annual General Meeting on Wednesday May 12, 2021.
In order to mitigate the spread of Covid-19, the Board of Directors has decided that the Annual General Meeting will be conducted by advance voting only, without physical presence of shareholders, proxies and third parties. Hansa Biopharma welcomes all shareholders to exercise their voting rights at this Annual General Meeting through advance voting on the basis of temporary statutory rules, according to the procedure set out below. Information on the resolutions passed at the Annual General Meeting will be published on May 12, 2021, as soon as the result of the voting has been finally confirmed.
SwedenStockholmUnited-kingdomFranceBelgiumSwedishAndreas-eggertHansa-biopharmaKlaus-sindahlEva-nilsagAnders-gersel-pedersenThomas-olausson